Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Caris Life Sciences' Q3 revenue rises on molecular profiling strength

By Reuters News


Overview

  • US molecular diagnostics firm's Q3 revenue rose 27% yr/yr, driven by molecular profiling growth

  • Net income fell yr/yr as operating expenses rose on headcount, R&D and marketing costs

  • Company raised 2026 revenue guidance to $1.04-$1.05 bln, up 28-29% yr/yr


Outlook

  • Caris Life Sciences expects 2026 revenue guidance of $1.04-$1.05 bln

  • Company reaffirms 2026 clinical therapy selection volume growth of about 20%


Result Drivers

  • MOLECULAR PROFILING GROWTH - Co said revenue growth was primarily driven by a 27% increase in molecular profiling services, attributed to higher clinical case volume and improved average selling prices

  • CLINICAL CASE VOLUME - Co completed approximately 61,500 clinical cases in Q3, up 21% yr/yr, supporting revenue growth

  • OPERATING EXPENSES - Higher headcount, R&D investment, and marketing spending contributed to a 42% rise in operating expenses


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$275.36 mln

Q3 Net Income

$15.25 mln

Q3 Income From Operations

$19.32 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Caris Life Sciences, Inc. is $30.00, about 8.7% below its November 3 closing price of $32.85

  • The stock recently traded at 94 times the next 12-month earnings vs. a P/E of 65 three months ago


Reuters Recommended Reads

  • Nov 4 - Charles River Laboratories Q3 revenue beats estimates, lifts 2026 outlook

  • Nov 3 - Stevanato Group Q3 revenue beats estimates on biopharma segment

  • Nov 3 - SOPHiA GENETICS Q3 revenue rises on US market strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.